Summary of Karyopharm Therapeutics Special Meeting Company Overview - **Company**: Karyopharm Therapeutics, Inc. (NasdaqGS: KPTI) - **Meeting Date**: February 18, 2026 - **Participants**: Richard Paulson (President, CEO, and Director), Michael Mano (Chief Legal Officer), Lori Macomber (Chief Financial Officer), Brendan Strong (Senior Vice President of Investor Relations) [1][2][3] Key Proposals Discussed 1. **Proposal One**: - Adoption and approval of an amendment to the restated certificate of incorporation to increase the number of authorized shares of capital stock from **58,333,333** to **111,000,000**. - Increase the number of authorized shares of common stock from **53,333,333** to **106,000,000** [7][9]. 2. **Proposal Two**: - Approval to adjourn the special meeting to a later date if necessary for further solicitation of proxies in case of insufficient votes for Proposal One [7][10]. Voting Results - A quorum was established with **18,310,283** shares of common stock entitled to vote present [5][6]. - Both proposals were approved based on preliminary voting results: - Proposal One to increase authorized shares was approved. - Proposal Two to allow for adjournment was also approved [9][10]. Important Notes - The meeting was conducted in a virtual format, allowing stockholders to participate similarly to an in-person meeting [2]. - Forward-looking statements were made, with a disclaimer regarding reliance on these statements due to potential differences in actual results [4]. - The final vote results will be documented in a Form 8-K to be filed within four business days after the meeting [10]. Additional Information - Stockholders were encouraged to submit questions related solely to the proposals during the meeting, but no questions were raised [7][8]. - The meeting concluded with gratitude expressed to shareholders for their participation and support [10].